drugset / Trial / NCT03165695

Ramelteon vs Placebo for Prevention of Delirium and Improvement of Sleep in Hospitalized Older Adults

NCT03165695

Phase 4 Withdrawn Brigham and Women's Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

This study evaluates whether Ramelteon can prevent delirium, decrease the severity of incident delirium and improve sleep wake cycle in hospitalized elderly surgical patients. Half of the patients will be assigned to Ramelteon, while other half will be assigned to placebo.

Timeline

Start
2019-12-01
Primary completion
2019-12-31
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 8 mg Oral

Indications